BSO, HRT, and ERT. No relevant financial disclosures
|
|
- April Carson
- 6 years ago
- Views:
Transcription
1 BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
2 Objectives To review the WHI data on MI, CVA, DVT, breast CA, and osteoporosis risk with ERT and HRT separately, in short and long term Describe actual risks of BSO on heart disease, CVA, osteoporosis stratified by age and use of ERT Review data surrounding estrogen after breast cancer Timeline 2002: Initial results released from WHI: suggested negative impact on breast cancer 2007: Updated results released - more balanced outcomes 2013: Parker study released: suggested ovaries should be retained
3 Impact of HRT-related decisions Among 500,000 women with vasomotor symptoms, patients who were untreated had 1.5 million more doctor visits = $340M = $27.7 M lost wages Patients with untreated vasomotor symptoms: 83% more doctor visits for any reason = $1346 / pt / year Women s Health Initiative (WHI) Study Review this trial with regard to effects on MI, CVA, osteoporosis, breast cancer, DVT, and all cause mortality Evaluate ESTROGEN effects (ERT) versus combined ESTROGEN-PROGESTERONE effects (HRT) - they are different Discuss short- and long-term effects Describe effect of age
4 -Grimes, Obstet Gynecol Grimes, Obstet Gynecol 2002
5 -Grimes, Obstet Gynecol 2002 Effects on MI / Cardiovascular disease Estrogen + Progesterone (n=16,608) Outcome HR CI Adjusted CI CV Disease Death from CV disease Nonfatal MI FU time 62 months -Grimes, Obstet Gynecol 2002
6 Update: Overall CV Events Compared ERT to HRT Trial HR CI Excess Risk per 10,000 person-yrs Combined Trials (ERT+HRT) Estrogen only Estrogen + Progesterone Rossauw, JAMA 2007 Update: Overall CV Events Compared ERT to HRT Trial HR CI Excess Risk per 10,000 person-yrs Combined Trials (ERT+HRT) Estrogen only Estrogen + Progesterone Rossauw, JAMA 2007
7 Age HR CI Protective in women Increased risk in women Rossauw, JAMA 2007 Bottom Line - Cardiovascular Disease Study criticism: unhealthy population may overestimate risk: 36% HTN, 49% smoked, 34% obese Improvement in Coronary Heart Disease in women (women up to 10 years after menopause) Increased risk in women (women further out from menopause Estrogen does not appear to be harmful - progesterone is the bad actor
8 -Grimes, Obstet Gynecol 2002 Effects on CVA Estrogen + Progesterone (n=16,608) Outcome HR CI Adjusted CI Stroke Fatal Nonfatal Stroke FU time 62 months -Grimes, Obstet Gynecol 2002
9 Update: Stroke Compared ERT to HRT Trial HR CI Excess Risk per 10,000 person-yrs Combined Trials (ERT+HRT) Estrogen only Estrogen + Progesterone Rossauw, JAMA 2007 Bottom Line - Stroke Risk is increased across the board, independent of age, time since menopause, or presence of progesterone
10 Effects on Venous TED (DVT/PE) Estrogen + Progesterone (n=16,608) Outcome HR CI Adjusted CI Venous TED DVT PE FU time 62 months -Grimes, Obstet Gynecol 2002 Bottom Line - Thromboembolic Disease Appears to be some risk, but the trial ended too early to be definitive for level of risk May be an early harm effect of HRT in first 2 years after use How I counsel patients: risk is 20-30/100,000 women, whereas risk of TED in pregnancy is 60/100,000 women!
11 -Grimes, Obstet Gynecol 2002 Effects on Breast Cancer Risk Estrogen + Progesterone (n=16,608) -Grimes, Obstet Gynecol 2002
12 July 2002: 26% increase in risk of breast cancer in treated women Actual meaning: <1 additional case of breast CA per 1000 women taking menopausal HRT above the baseline risk of 3-4 per 1000 per year - not statistically significant How I counsel patients: risk is 20-30/100,000 women, whereas risk of TED in pregnancy is 60/100,000 women! That statement yielded a 27-80% decrease in the use of ERT / HRT
13 Women using HRT had fewer metastases and better prognosis tumors ERT did NOT show a significant increase in breast CA incidence - only HRT...even in the 2002 report The ESTROGEN-ONLY arm data released in 2004 showed a technically not significant reduction in breast CA after 7 years of ERT No increase in breast CA in the women with no prior HRT use (this was not announced)
14 Effects on Fractures Estrogen + Progesterone (n=16,608) Outcome HR CI Hip Vertebral Other Total FU time 62 months -Grimes, Obstet Gynecol 2002 Bottom Line - Osteoporosis ERT-only trial: 35-39% reductions in fracture with improvement in bone mineral density Fractures decreased for ERT and HRT
15 How do we put this together? How do we put this together?
16 Global Index (by age and treatment) Risk profile improved with estrogen only Protective ages 50-59, neutral age 60-69, increased risk ages How do we put this together?
17 Conclusions There were no significant increases in risk due to hormone therapy for any outcome at ages years There was a reduction in total mortality in the age group of years...10 fewer deaths per person years in the treated group. This compared with 16 additional deaths at ages years. -Rossauw, JAMA 2007 Bottom Line Cardiovascular disease and MI: may be improved in women close to menopause, especially on ERT DVT/PE: probably increased risk Breast cancer: NO increased risk with ERT alone Osteoporosis / Fracture risk: improved with ERT or HRT Global index improved and lower mortality, especially in women age on estrogen-alone therapy -Rossauw, JAMA 2007
18 Take Home Message ERT and HRT are relatively safe for women under age 70 ERT is safer than HRT - very safe profile But use ERT with caution in women 70 or over Informed consent is important -Rossauw, JAMA 2007 BSO What are the current data surrounding removal of ovaries and Fallopian tubes? When we counsel our patients, what are the real risks? -Rossauw, JAMA 2007
19 BSO Hysterectomy is the 2nd most common surgery for women in the US It is common practice to remove ovaries at that time in women in mid-40 s and up - reduces ovarian cancer risk, prevents future surgery, assumes ERT given Patients at risk for hereditary cancers should have ovaries removed -Rossauw, JAMA 2007 Causes of Hereditary Susceptibility to Ovarian Cancer Sporadic BRCA1 (~70-75%) Hereditary (~10%) Other single genes (<5%) HNPCC (~2%) BRCA2 (~20%)
20 Hereditary Breast Ovarian Syndrome 90% 68% 46% Risk General Population HBOC 45% 23% 0% Ovarian Breast Schorge et al Gynecol Oncol 2010 Lynch Syndrome (HNPCC) 80% 60% 40% General Population HNPCC women HNPCC men 20% 12% Risk 0% Ovarian Uterine Colon Schorge et al Gynecol Oncol 2010
21 Occult cancers in risk reducing salpingooophorectomy samples from BRCA mutation carriers 1-Ovulation causes genotoxic stress 2-DNA damage occurs in FT 3 - TIN occurs when there is a DNA repair deficiency (BRCA+) Levanon K, JCO 26:5284, 2008
22 BRCA1/2 Rate of unsuspected neoplasia at RRSO is % Hazard ratio for breast or BRCA-related gyn cancer = 0.25 (95% CI, ) - a 75% reduction in risk!!! Connor Gynecol Oncol 2014; Finch JAMA 2006; Powell Int J Gynecol Cancer 2011; Kauff NEJM 2002 BRCA1/2 Decreases breast CA up to 50% Decreases ovarian CA risk by 85-95% Improves overall mortality Connor Gynecol Oncol 2014; Finch JAMA 2006; Powell Int J Gynecol Cancer 2011; Kauff NEJM 2002
23 BRCA1/2 What about ERT or HRT after RRSO? Important to discuss menopausal side effects before surgery and have a plan in place RRSO with short term HRT was still associated with a profound reduction in breast cancer risk in carriers of BRCA1 and BRCA2 mutations HR = 0.37 (95% CI, 0.14 to 0.96) -Rebbeck TR, et al. J Clin Oncol 2005 What about in benign wildtype patients who have oophorectomy? -Rossauw, JAMA 2007
24 122, 700 RN s enrolled in NHS in ,380 women had a hysterectomy for benign disease 16, 345 women (55.6%) had BSO 13, 035 (44.4%) kept ovaries - ovarian conservation To consider what diseases and conditions women died from in the years after their surgery over 28 years of follow up
25 Ovarian cancer risk reduction: largest benefit to high risk women 44 of 13,305 women (0.9%) who kept ovaries got ovarian cancer (4 vs 44 women) BSO reduced but did not eliminate risk of ovarian cancer Breast CA risk reduction (HR 0.6 if <45 y) - 25% less breast CA
26 Long-term health risk - heart disease, stroke, and lung cancer are more common in this group in the NHS study All cause mortality, CV disease, stroke, cognitive function, neurologic disease, depression, anxiety, sexual dysfunction, osteoporosis CHD: HR 1.26 for women <45 yo with both ovaries removed Not a healthy population: 1/3 smokers Risk of CV disease and stroke in this population does not take into account the use of ERT post-hysterectomy MUCH higher risk among never-users of ERT: CV disease HR 1.98 and stroke HR 2.19 in never-users of ERT <45 yo ESTROGEN USE MATTERS! ERT after BSO reduces risk!
27 Bottom Line on Risk of BSO For women under 50 years old at time of hysterectomy, BSO was associated with increased mortality after oophorectomy - Only in never users of ERT - NOT in past or current users of ERT - Study confounded by an unhealthy population with CV risk factors - 1/3 were smokers and there was a high risk of lung cancer in this populationrisk of CV disease and stroke in this population does not take into account the use of ERT post-hysterectomy ESTROGEN USE MATTERS! ERT after BSO reduces risk! Are there other confirmatory studies? NHS: younger women who did not take ERT were at the highest risk - OR 1.4 (95% CI ) - Increase in mortality from lung CA - Increased risk for CAD Mayo Cohort Study confirmed this - HR 1.67 (95% CI ) - Risk higher if <45 yo and no ERT WHS: no difference in any age group
28 My interpretation: Faulty take-home message. Should be that ERT is important after BSO Update on NHS 30,117 patients underwent hysterectomy +/- BSO BSO associated with a lower risk of death from ovarian or breast cancer BSO NOT associated with lower overall or cause-specific mortality Women <50 yo at time of BSO who were never-users of ERT had a higher mortality (HR 1.41) - also had an increase in CHD and lung cancer These risks were NOT seen in women who were past or current users of ERT (HR 1.05)
29 2013 Update on NHS My take-home: NO increased risk to BSO even in women <50 years old as long as ERT is prescribed post-operatively How to proceed? Evaluate indication for oophorectomy Evaluate menopausal status (post-menopausal patients may be risk-neutral) Counsel appropriately Consider that BSO followed by ERT does not appear to confer risk and does protect against breast and ovarian cancer
30 What about in patients with a history of breast cancer? Long term results of breast cancer outcomes are favorable Median FU 11.8 years ERT use (median = 5.9 y) was associated with a lower incidence of invasive breast CA: HR 0.77, 95% CI Consider that BSO followed by ERT does not appear to confer risk and does protect against breast and ovarian cancer Lower mortality in ERT arm: HR 0.37, 95% CI
31 Breast Cancer Incidence Lower Incidence Anderson, Lancet Oncol 2012 Breast Cancer Mortality Lower Incidence Anderson, Lancet Oncol 2012
32 All Cause Mortality after Breast Cancer Lower Mortality Anderson, Lancet Oncol of 219 HRT patients and 7 of 215 non-hrt patients had a new breast cancer event so the trial was stopped early
33 Favorable results: 288 patients with breast cancer received HRT Median FU 10 years No difference in new breast cancer events, mortality, or new primary malignancies More patients had contralateral breast CA in the HRT group (Eur J Cancer, 2013) Since estrogen thought to increase breast cancer recurrence, suggest that ERT is contraindicated in women with breast CA EXCEPT some symptomatic women with BRCA mutations who have ER- breast cancers, preferably post mastectomy
34 My Plan Evaluate Counsel risk pre-operatively Consider pre-operative genetic testing/ counseling ERT for post-bso patients at least until age 59 Thank you!
Long-Term Health Outcomes of Surgical Menopause
Long-Term Health Outcomes of Surgical Menopause Vanessa Jacoby, MD, MAS Associate Professor Obstetrics, Gynecology, and Reproductive Sciences University of California, San Francisco None Disclosures Overview
More informationHereditary Gynecologic Cancer 15 Years of Progress
Hereditary Gynecologic Cancer 15 Years of Progress Bethan Powell, M. D. Kaiser Permanente UCSF Gynecologic Cancer Risk Program Hereditary Gynecologic Cancer Syndromes BRCA 1 and 2: ovarian Lynch: ovarian/endometrial
More informationInherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions
Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions Noah D. Kauff, MD, FACOG Director, Clinical Cancer Genetics Duke Cancer Institute / Duke University Health System Disclosures
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationInherited Ovarian Cancer Diagnosis and Prevention
Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More information6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention
6 Week Course Agenda Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention Lee-may Chen, MD Director, Division of Gynecologic Oncology Professor Department of Obstetrics, Gynecology
More informationRisk-reducing surgery and hormones
Risk-reducing surgery and hormones Nora Johansen Registrar and PhD student at Department of Obstetrics and Gynecology, Sørlandet Hospital Arendal, Norway No conflicts of interest to declare Overview Hereditary
More informationTumori eredofamiliari: sorveglianza di donne ad alto rischio
Tumori eredofamiliari: sorveglianza di donne ad alto rischio 14/01/2018 Dott Matteo Generali AUSL Modena Carpi U.O. Ostetricia e Ginecologia Screening for gynaecologic cancer in genetically predisposed
More informationOVARIAN CANCER Updates in Screening, Early Detection and Prevention
UW MEDICINE SUSAN PATRICIA TECK MEMORIAL LECTURE October 2017 OVARIAN CANCER Updates in Screening, Early Detection and Prevention BARBARA GOFF, MD Seattle Gynecologic Society March 2018 OVARIAN CANCER
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationHORMONE REPLACEMENT THERAPY
TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationIMPLICACIONES DE LA OOFORECTOMÍA PROFILÁCTICA Y EL USO DE TRH SOBRE LA MORTALIDAD FEMENINA XIII
IMPLICACIONES DE LA OOFORECTOMÍA PROFILÁCTICA Y EL USO DE TRH SOBRE LA MORTALIDAD FEMENINA XIII Congreso Costarricense de Climaterio Menopausia y osteoporosis 2014 Dr. Leonardo Orozco S. Colaboración Cochrane
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationIs It Time To Implement Ovarian Cancer Screening?
Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationRisk Reduction management for Ovarian Cancer in Women with BRCA1/2 Mutation
Risk Reduction management for Ovarian Cancer in Women with BRCA1/2 Mutation Global Breast Cancer Conference 2018 2018. 4. 6 (Fri) Songdo, Incheon, Korea Hereditary Gynecologic Cancer Clinic Precision Medicine
More informationFinding Our Reasons to Choose Estrogen PRE- HRT. Learning Objectives. Disclosure. Learning Objectives. Replacement Therapy. For Previvors 6/1/17
Hormone Replacement Therapy Mefile:///Reimagined: How to Look Hot and Feel Healthy For Previvors Without Fear and Confusion Mache Seibel, MD HRT PRE- FOR VIVORS Mache Seibel, MD DrMache.com Disclosure
More informationHeart Disease in Women: Is it Really Different?
Heart Disease in Women: Is it Really Different? Jennifer Jarbeau, MD Southcoast Physicians Group Cardiovascular Associates of RI Disclosures I have no financial interests to disclose I wish I did! Are
More informationPolicy #: 259 Latest Review Date: November 2009
Name of Policy: Prophylactic Oophorectomy Policy #: 259 Latest Review Date: November 2009 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates.
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More information1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45
1 2 3 1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women
More informationpatient education Fact Sheet
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations OCTOBER 2017 BRCA1 and BRCA2 Mutations Cancer is caused by several different factors. A few types of cancer run in families. These types are
More informationSurgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk
Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationBiology Response Controversies and Advances
Biology Response Controversies and Advances in BRCA related ovarian cancer Lessons learned and future directions Michael Friedlander The Prince of Wales Hospital and Royal Hospital for Women Sydney BREAST-CANCER
More informationManagement of BRCA mutation carriers
Management of BRCA mutation carriers Clinical Case Presentation Shani Paluch-Shimon, MBBS, MSc Head, Breast Cancer Service for Young Women Oncology Institute Sheba Medical Center, Israel esmo.org DISCLOSURES
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationOvarian Cancer Causes, Risk Factors, and Prevention
Ovarian Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for ovarian cancer.
More informationUPDATE: Women s Health Issues
UPDATE: Women s Health Issues Renee B. Alexis, MD, MBA, MPH, FACOG Associate Professor Department of OBGYN Kiran C. Patel College of Osteopathic Medicine Disclosure of Conflicts of Interest I have no financial
More informationPrevention, Diagnosis and Treatment of Gynecologic Cancers
Prevention, Diagnosis and Treatment of Gynecologic Cancers Jubilee Brown MD and Pamela T. Soliman MD, MPH Department of Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer
More informationFAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions
ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are
More informationNorth American Menopause Society (NAMS)
North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College
More informationManaging the adnexae at the time of hysterectomy for benign gynaecological disease
Managing the adnexae at the time of hysterectomy for benign gynaecological disease This statement has been developed and reviewed by the Women s Health Committee and approved by the RANZCOG Board and Council.
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationAsk the Experts Obstetrics & Gynecology
1 Management of the Adnexal Mass James H. Liu, MD, and Kristine M. Zanotti, MD June 2011 Volume 117 Issue 6 Pages 1413 28 Click Here to Read the Full Article Questions written by: Rini Banerjee Ratan,
More informationHormone Replacement Therapy (HRT) Benefits & Risks - The Facts
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationIncreased Risk of Breast Cancer: Screening and Prevention. Elizabeth Pritchard, MD 4/5/2017
Increased Risk of Breast Cancer: Screening and Prevention Elizabeth Pritchard, MD 4/5/2017 No disclosures Defining Risk Risk Factors Modifiable Lifestyle obesity physical activity alcohol consumption breast
More informationDisclosure. Objectives
Charles A. Leath, III, MD, MSPH Associate Professor University of Alabama at Birmingham Disclosure I have no potential financial or other conflicts of interest. The view(s) expressed herein are those of
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer. HBOC related genes. I have nothing to disclose
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program I have nothing to disclose Key Recommendations
More informationUterine Morcellation: Teasing Out the Issues
Uterine Morcellation: Teasing Out the Issues Stacey A. Scheib, MD, FACOG Director, Minimally Invasive Gynecology Director, Hopkins Multidisciplinary Fibroid Center Johns Hopkins Hospital Disclosures I
More informationLessons learned for the conduct of a successful screening trial
Lessons learned for the conduct of a successful screening trial Christine D. Berg, M.D. Adjunct Professor Department of Radiation Oncology Johns Hopkins Medicine IOM State of the Science in Ovarian Cancer
More informationBRCA mutation carrier patient: How to manage?
BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE
More informationHereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families
Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast and Ovarian Cancer is a genetic condition which
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationChristine Garcia, MD 1, Liisa Lyon, MS 2, Ramey D. Littell, MD 1 and C. Bethan Powell, MD 1
American College of Medical Genetics and Genomics Comparison of risk management strategies between women positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations
More informationSurgical treatment of BRCA mutated patients. Viviana Galimberti MD European Institute of Oncology Milan, Italy
Surgical treatment of BRCA mutated patients Viviana Galimberti MD European Institute of Oncology Milan, Italy No pharmaceutical company funding was used I declare I have no conflicts of interest as regards
More informationPharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting Disclosure
Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting 2015 Disclosure The faculty and planners for this activity, as well as the CME staff, do not have any relevant
More informationOvaries: In Sickness and Health. Mr N Pisal Consultant Gynaecologist The Portland Hospital
Ovaries: In Sickness and Health Mr N Pisal Consultant Gynaecologist The Portland Hospital Topics for discussion How to assess ovarian function? AMH PCOS Ovarian pain Ovarian cysts Ovarian screening Menopause
More informationGenetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction
Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction Forum INCA-ASCO sobre Cancer Hereditario e Predisposicao Genetica ao Cancer Jeffrey N. Weitzel, M.D. Professor of Oncology
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationInformation leaflet for women with an increased lifetime risk of breast and ovarian cancer. Hereditary Breast and Ovarian Cancer (HBOC)
Information leaflet for women with an increased lifetime risk of breast and ovarian cancer Hereditary Breast and Ovarian Cancer (HBOC) What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationTopics. BRCA 1 and BRCA 2 Mutations. Breast cancer BRCA1 / BRCA BRCA 1 und BRCA 2 Mutations and hormonal therapy
BRCA 1 and BRCA 2 Mutations Recommendations for Contraception PD G.Merki USZ Breast Cancer risk Topics Breast Cancer risk and hormonal Contraception BRCA 1/2 mutations and changes in risk for breast and
More informationEffective Health Care Program
Comparative Effectiveness Review Number 17 Effective Health Care Program Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women Executive Summary Background Breast cancer
More informationControversies in Primary Care Pros and Cons of HRT on patients with CHD
Controversies in Primary Care Pros and Cons of HRT on patients with CHD Claire Bellone MSc Clinical Nurse Specialist Menopause Nottingham Declaration Honorariums & Sponsorship from Bayer, Novonortis, Wyeth
More informationRisk Assessment, Genetics, and Prevention
Risk Assessment, Genetics, and Prevention Katherine D. Crew, MD MS Director, Clinical Breast Cancer Prevention Program Columbia University Medical Center 1 Outline Breast cancer risk factors Hereditary
More informationOBJECTIVES 8/25/2017. An attempt to organize the chaos
High Risk for Breast Cancer and Genetics: Who? What? Where? When? An attempt to organize the chaos Presented at Winds of Change Conference November 3, 2017 by Carol Hager, MSN, CRNP and Allison Haener,
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationControversies in Preventative Cardiology
Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence
More informationHRT & Menopause Where Do We Stand Now?
HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by
More informationAlcohol & Cancer: from prevention to the patient
Alcohol & Cancer: from prevention to the patient -from consistency to inconsistencies- Ellen Kampman Wageningen University Academic Medical Centre St Radboud Nijmegen 23 september 2010 Alcohol and the
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More information--- or not, and do we need to come up with newer strategies for ovarian cancer screening.
My name is Dr. Karen Lu and I am a Professor of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. I also serve as Co-Medical Director for Clinical Cancer Genetics. I m going to
More informationLynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
More informationSpectrum of Care Options for Women at High Risk for Breast and Ovarian Cancer
Spectrum of Care Options for Women at High Risk for Breast and Ovarian Cancer Sheryl G.A. Gabram, MD, MBA, FACS Professor of Surgery, Emory University Director, High Risk Assessment Program Winship Cancer
More informationPartners: Introductions: Dr. Carolyn Johnston Deanna Cosens & Ann Garvin. Ovarian Cancer and Primary Care July 16, :00 9:00am EST 7/16/2014
Welcome To The Webinar Technical Support Ovarian Cancer and Primary Care July 16, 2014 8:00 9:00am EST In order to hear the presentation please call 1 (626) 544-0058, access code 167-314-644, followed
More informationSurgery to reduce the risk of ovarian cancer
Surgery to reduce the risk of ovarian cancer INFORMATION FOR PATIENTS This leaflet is designed to answer questions you may have about surgery to reduce your risk of ovarian cancer. You may be considering
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationTreatment issues for women with BRCA germline mutation
Treatment issues for women with BRCA germline mutation Overview Fertility and reproductive lifespan The impact of reproductive life on breast and ovarian cancer risk Screening recommendations during pregnancy
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION. Women who carry a germline mutation in
VOLUME 22 NUMBER 12 JUNE 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Kelly Metcalfe, Henry T. Lynch, Parviz Ghadirian,
More informationGenetic Determinants, Risk Assessment and Management
Genetic Determinants, Risk Assessment and Management Rachel Rando, MS, CGC Genetic Counselor Hunterdon Regional Cancer Center Flemington, NJ I have no disclosures. Acknowledgements: Staff of Hunterdon
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationBreast Cancer: Selected Topics for the Primary Care Clinician
Breast Cancer: Selected Topics for the Primary Care Clinician Leah Karliner, MD MAS October 2009 Primary Care Medicine: Principles and Practice OUTLINE Incidence and Mortality Risk Factors and Risk Reduction/Prevention
More informationMenopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D
Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D Menopause and Cancer How does menopause affect a woman s cancer risk? Ø Menopause does not cause cancer.but risk of developing
More informationHormone replacement therapy and breast density after surgical menopause
Hormone replacement therapy and breast density after surgical menopause Freya Schnabel*; Sarah Pivo; Esther Dubrovsky; Jennifer Chun; Shira Schwartz; Amber Guth; Deborah Axelrod Department of Surgery,
More informationINTRODUCTION BREAST CANCER CARE
INTRODUCTION Breast Cancer Care welcomes the HFEA s consultation on embryo selection for inherited cancer. This is an extremely important and complex issue. Because of this, Breast Cancer Care has encouraged
More informationDINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC
DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationRisk-reducing Surgery in BRCA mutation carriers
Risk-reducing Surgery in BRCA mutation carriers Daerim St. Mary s Hospital Department of Surgery, Breast Care Center Hereditary Breast Ovarian Cancer Clinic Sung-Won Kim, MD, PhD, FACS Overview of HBOC
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationFinding the gaps between national guidelines and patient decisions in the hereditary cancer community
Finding the gaps between national guidelines and patient decisions in the hereditary cancer community Lisa Rezende, PhD Vice President/Education FORCE: Facing Our Risk of Cancer Empowered The ABOUT Network
More informationLOBULAR CARCINOMA IN SITU: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE
: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University of Washington Joint Member, Fred Hutchinson Cancer
More informationDoes Cancer Run in Your Family?
Does Cancer Run in Your Family? A Patient s Guide to Hereditary Breast and Ovarian Cancer Syndrome What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More informationInterpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining
Stains for Tumor Classification p53 p16 WT1 HMGA2 P53 Mutations are Ubiquitous in High Grade Serous Carcinoma Source Ahmed et al Australian Ovarian Cancer Study Cancer Genome Atlas Research Network Cases
More informationMANAGEMENT OF HIGH RISK BREAST PATIENTS DR PAMELA THOMPSON BREAST PHYSICIAN, FSH
MANAGEMENT OF HIGH RISK BREAST PATIENTS DR PAMELA THOMPSON BREAST PHYSICIAN, FSH HIGH RISK MANAGEMENT OBJECTIVES Be alert to FHx Breast and/or Ovarian cancer Know how to perform a risk assessment Be aware
More informationWhat is the gynecologist s role in the care of BRCA previvors?
What is the gynecologist s role in the care of BRCA previvors? Here, your patient s options for surgery and your best options for her follow-up care and ongoing surveillance OBG Manag. Sept 2013;25(9):10-14.
More information